含泊马度胺的方案治疗复发难治性多发性骨髓瘤的有效性和安全性  

Efficacy and safety of pomalidomide-containing regimen in the treatment of relapsed or refractory multiple myeloma

作　　者：宾燕成 李虎生[1] 叶光剑 阮光靖[2] BIN Yancheng;LI Husheng;YE Guangjian;RUAN Guangjing(Red Cross Hospital of Yulin City,Yulin 537000;the Fourth People's Hospital of Nanning,Nanning 530012,China)

机构地区：[1]玉林市红十字会医院,广西玉林537000 [2]南宁市第四人民医院,广西南宁530012

出　　处：《临床医学研究与实践》2025年第6期33-36,共4页Clinical Research and Practice

基　　金：广西壮族自治区卫生健康委自筹经费科研课题(No.Z-A20231210)。

摘　　要：目的 探讨含泊马度胺的方案治疗复发难治性多发性骨髓瘤(RRMM)的有效性和安全性。方法 选取2021年7月至2022年8月于玉林市红十字会医院接受含泊马度胺方案治疗的46例RRMM患者作为研究对象,观察其临床疗效、不良反应发生情况,并进行生存分析。结果 2个疗程后患者的总缓解率(ORR)为58.70%(27/46),4个疗程后患者的ORR为80.49%(33/41),两者比较,差异具有统计学意义(P<0.05);在亚组分析中,12例伴高危细胞遗传学异常(HRCAs)患者的ORR为33.33%,34例不伴HRCAs患者的ORR为76.47%,两者比较,差异具有统计学意义(P<0.05);19例伴髓外病变患者的ORR为68.42%,27例不伴髓外病变患者的ORR为62.96%,两者比较,差异无统计学意义(P>0.05)。治疗期间的不良反应主要有白细胞减少、血小板减少、贫血、感染、乏力、周围神经病变。每例患者均随访24个月,中位无进展生存时间(PFS)为9个月,中位总生存时间(OS)为11.6个月。结论 含泊马度胺的方案治疗RRMM的有效性和安全性较高,为临床治疗提供了新的选择。Objective To investigate the efficacy and safety of pomalidomide-containing regimen in the treatment of relapsed or refractory multiple myeloma(RRMM).Methods A total of 46 patients with RRMM who were treated with pomalidomide-containing regimen in Red Cross Hospital of Yulin City from July 2021 to August 2022 were selected as the research objects.The clinical efficacy and adverse reactions were observed,and survival analysis was conducted.Results The overall response rate(ORR)of patients after 2 courses of treatment was 58.70%(27/46),the ORR of patients after 4 courses of treatment was 80.49%(33/41),and the difference was statistically significant(P<0.05);in subgroup analysis,the ORR of 12 patients with high-risk cytogenetic abnormalities(HRCAs)was 33.33%,while the ORR of 34 patients without HRCAs was 76.47%,and the difference was statistically significant(P<0.05);the ORR of 19 patients with extramedullary lesions was 68.42%,while the ORR of 27 patients without extramedullary lesions was 62.96%,and the difference was not statistically significant(P>0.05).The main adverse reactions during treatment were leukopenia,thrombocytopenia,anemia,infection,fatigue and peripheral neuropathy.Each patient was followed up for 24 months,with a median progression-free survival(PFS)of 9 months and a median overall survival(OS)of 11.6 months.Conclusion Pomalidomide-containing regimen in the treatment of RRMM has high efficacy and safety,which provides a new choice for clinical treatment.

关 键 词：复发难治性多发性骨髓瘤 泊马度胺 无进展生存时间 总生存时间 

分 类 号：R733.3[医药卫生—肿瘤]